Rifampin Injection shortage
Current 4 presentations · 3 manufacturers · first FDA posting Feb 17, 2021 · last update Oct 15, 2026
Manufacturers: Fresenius Kabi USA, LLC, Mylan Institutional, a Viatris Company, Sanofi-Aventis U.S. LLC
Stated reasons (per FDA): Demand increase for the drug; Discontinuation of the manufacture of the drug; Other
More info: FDA Drug Shortages Database · ASHP drug shortages list (search there for this drug)
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Rifampin, Injection, 600 mg (NDC 63323-351-20) | Fresenius Kabi USA, LLC | Current Limited Availability |
Other | Check wholesalers for inventory | Posted Feb 17, 2021 Updated Oct 15, 2026 |
| Rifampin, Injection, 600 mg (NDC 67457-445-60) | Mylan Institutional, a Viatris Company | Current Unavailable |
Demand increase for the drug | Estimated recovery: Q4 2026 | Posted Feb 17, 2021 Updated Oct 5, 2026 |
| Rifadin, Injection, 600 mg (NDC 0068-0597-01) | Sanofi-Aventis U.S. LLC | Current Unavailable |
Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Posted Feb 17, 2021 Updated Sep 18, 2026 |
| Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted Apr 20, 2026 Updated Apr 20, 2026 Discontinued Apr 20, 2026 |